Astrazeneca (AZN) Non-Current Deferred Tax Liability (2009 - 2026)

Astrazeneca has reported Non-Current Deferred Tax Liability for 18 years, with the latest figure at -$3.5 billion in Q2 2026.

• On a quarterly basis, Non-Current Deferred Tax Liability rose 4.2% year-over-year to -$3.5 billion in Q2 2026; TTM through Jun 2026 was -$3.5 billion, a 4.2% increase from a year earlier, with the FY2025 full-year figure at -$3.5 billion, down 5.9% from the prior year.
• Non-Current Deferred Tax Liability was -$3.5 billion for Q2 2026 at Astrazeneca, roughly flat from -$3.5 billion in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was -$2.6 billion in Q1 2024, with the low at -$5.6 billion in Q1 2022.
• Average Non-Current Deferred Tax Liability over 5 years is -$3.5 billion, with a median of -$3.5 billion recorded in 2026.
• The largest YoY upside for Non-Current Deferred Tax Liability was 52.56% in 2022 against a maximum downside of 99.29% in 2022.
• Over 5 years, Non-Current Deferred Tax Liability stood at -$2.9 billion in 2022, then advanced by 3.4% to -$2.8 billion in 2023, then decreased by 16.21% to -$3.3 billion in 2024, then retreated by 5.9% to -$3.5 billion in 2025, then gained by 1.06% to -$3.5 billion in 2026.
• The last three Non-Current Deferred Tax Liability figures came in at -$3.5 billion (Q2 2026), -$3.5 billion (Q1 2026), and -$3.5 billion (Q4 2025), per Business Quant data.